We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prevalence and predictive features of metabolic dysfunction-associated steatotic liver disease in type 1 diabetes.
- Authors
Snethlage, Coco M Fuhri; Meijnikman, Abraham S; Mak, Anne Linde; Rampanelli, Elena; Voermans, Bas; Callender, Cengiz A K; Groen, Pleun de; Roep, Bart O; Raalte, Daniël H van; Knop, Filip K; Holleboom, Adriaan G; Nieuwdorp, Max; Hanssen, Nordin M J
- Abstract
Aims/hypothesis The prevalence and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 1 diabetes remain unclear. Therefore, we investigated the prevalence and severity of MASLD in type 1 diabetes and assessed which clinical features are most important in predicting MASLD severity. Methods A total of 453 individuals with type 1 diabetes (41.6 ± 15.0 years, 64% female, body mass index [BMI] 25.4 ± 4.2 kg/m2, and HbA1c 55.6 ± 12 mmol/mol) underwent vibration-controlled transient elastography (VCTE), with a controlled attenuation parameter (CAP) score for steatosis (≥ 280.0 dB/m) and a liver stiffness measurement (LMS) for fibrosis (≥ 8.0 kPa). A machine learning Extra-Trees classification model was performed to assess the predictive power of the clinical features associated with type 1 diabetes with respect to steatosis and fibrosis. Results The prevalence of hepatic steatosis and fibrosis was 9.5% (95% CI, 6.8-12.2) and 3.5% (95% CI, 1.8-5.2). Higher LMS was associated with a longer duration of type 1 diabetes (median 30.5 [IQR 18.0-39.3] years vs 15.0 [IQR 6.0-27.0] years), and individuals were older, had a higher BMI (mean 27.8 ± 5.2 vs 25.3 ± 4.1 kg/m2), and a higher CAP score (mean 211.4 ± 51.7 dB/m vs 241.4 ± 75.6 dB/m). The most important predictive features of fibrosis were duration of type 1 diabetes, age, and systolic blood pressure, with a mean ± SD area under the curve of 0.73 ± 0.03. Conclusion Individuals with type 1 diabetes and high blood pressure, older age, higher BMI, and longer duration of disease could be considered at high-risk for developing MASLD.
- Subjects
TYPE 1 diabetes; LIVER diseases; SYSTOLIC blood pressure; HYPERTENSION; FATTY liver
- Publication
European Journal of Endocrinology, 2024, Vol 190, Issue 5, p391
- ISSN
0804-4643
- Publication type
Article
- DOI
10.1093/ejendo/lvae043